Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy

This is a prospective, multicenter, randomized, parallel controlled study to evaluate the effectiveness of Huaier Granule in preventing recurrence and metastasis after radical resection of colorectal cancer

Trial Details

NCT ID
NCT06090994
Phase
PHASE4
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Huaier granule
  • Capecitabine
Locations (sample)
  • Harbin, Heilongjiang, China|45.75,126.65
  • Changzhou, Jiangsu, China|31.77359,119.95401
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Yangzhou, Jiangsu, China|32.39722,119.43583
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥ 18 years old, regardless of gender.
  • It is diagnosed as colorectal cancer by histopathology, TNM stage Ⅱ.
  • Received radical resection of colorectal cancer (R0) within 12 weeks prior to enrollment.
  • Not receiving neoadjuvant therapy before surgery, and not receiving any adjuvant therapy after surgery.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →